Skip to main content

Advertisement

SpringerLink
Log in

Effect of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of prostate cancer patients

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to determine whether the presence of IL-18 polymorphisms -137 G/C and -607 A/C was associated with grade, clinical stage, and survival in patients with prostate cancer.

Methods

The study cohort included 126 patients with prostate cancer. Control group consisted of 125 samples from Chinese population. Genomic DNA was extracted from EDTA-anticoagulated peripheral blood leukocytes by the salting-out method. The genotyping of the two IL-18 polymorphisms was performed using predesigned TaqMan SNP Genotyping Assays.

Results

The studied IL-18 gene polymorphisms did not influence susceptibility to prostate cancer in the analyzed group of patients (IL-18-607, P = 0.342; IL-18-137 P = 0.715) but may contribute to disease onset and aggressiveness. IL-18-607 CC genotype was significantly associated with higher tumor grade (P = 0.025) and stage (P = 0.001). IL-18-137 GG genotype was correlated with higher tumor grade (P = 0.018) and stage (P = 0.007). The Cox proportional hazard model showed that tuumor grade and stage grouping were independent prognostic factors but IL-18 polymorphism was not. Polymorphism variants in the IL-18 gene (IL-18-607 and IL-18-137) may be associated with a worse prognosis for prostate cancer.

Conclusion

High levels of IL-18 production may play a major role in the growth, invasion and metastasis of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol, 2012, 30: 195–200.

    Article  PubMed  Google Scholar 

  2. Vijayalakshmi K, Vettriselvi V, Krishnan M, et al. Cytochrome p4501A1gene variants as susceptibility marker for prostate cancer. Cancer Biomark, 2005, 1: 251–258.

    PubMed  CAS  Google Scholar 

  3. Anisimova NY, Sosnov AV, Ustyuzhanina NE, et al. Cytotoxic activity of peripheral blood mononuclear leukocytes, activated by interleukin-2/beta-cyclodextrin nanocomposition against androgen receptornegative prostate cancers. Oncology, 2011, 2011: 405656.

    Google Scholar 

  4. Kato T, Nakane K, Kojima T, et al. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression. Biochem Biophys Res Commun, 2012, 417: 966–971.

    Article  PubMed  CAS  Google Scholar 

  5. Dziedziejko V, Kurzawski M, Paczkowska E, et al. Association between IL-18 gene polymorphisms and the release of interleukin-18 from stimulated peripheral blood mononuclear cells. Postepy Hig Med Dosw, 2012, 66: 409–414.

    Article  Google Scholar 

  6. Lebel-Binay S, Thiounn N, De Pinieux G, et al. IL-18 is produced by prostate cancer cells and secreted in responseto interferons. Int J Cancer, 2003, 106: 827–835.

    Article  PubMed  CAS  Google Scholar 

  7. Hikosaka S, Hara I, Miyake H, et al. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int J Urol, 2004, 11: 647–652.

    Article  PubMed  CAS  Google Scholar 

  8. Nong SJ, Wen DG, Fan CB, et al. Clinical value of Serum Interleukin-18 in patients with prostate cancer. Chinese-German J Clin Oncol, 2007, 6: 574–578.

    Article  CAS  Google Scholar 

  9. Nong SJ, Zhang YP, Zhou SJ, et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer. Chinese-German J Clin Oncol, 2010, 9: 643–647.

    Article  CAS  Google Scholar 

  10. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 2007, 4: 329–335.

    PubMed  CAS  Google Scholar 

  11. Haghshenas MR, Hosseini SV, Mahmoudi M, et al. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol, 2009, 24: 1119–1122.

    Article  PubMed  CAS  Google Scholar 

  12. Yang J, Xu DL, Lu Q, et al. Prostate cancer risk and aggressiveness associated with the CYP1B1 4326C/G (Leu432Val) polymorphism: a meta-analysis of 2788 cases and 2968 controls. Asian J Androl, 2012, 14: 560–565.

    Article  PubMed  CAS  Google Scholar 

  13. Vainrib M, Golan M, Amir S, et al. HIF1A C1772T polymorphism leads to HIF-1 alpha mRNA overexpression in prostate cancer patients. Cancer Biol Ther, 2012, 13: 720–726.

    Article  PubMed  CAS  Google Scholar 

  14. Ye ZB, Ma T, Li H, et al. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol, 2007, 13: 1747–1751.

    Article  PubMed  CAS  Google Scholar 

  15. Eissa SA, Zaki SA, El-Maghraby SM, et al. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst, 2005, 17: 51–55.

    PubMed  Google Scholar 

  16. Cho D, Song H, Kim YM, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 2000, 60: 2703–2709.

    PubMed  CAS  Google Scholar 

  17. Farhat K, Hassen E, Bouzgarrou N, et al. Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine, 2008, 43: 132–137.

    Article  PubMed  CAS  Google Scholar 

  18. Liu Y, Lin N, Huang L, et al. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol, 2007, 26: 613–618.

    Article  PubMed  CAS  Google Scholar 

  19. Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, et al. Heterozygosity for interleukin-18 -607A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res, 2007, 27: 3849–3853.

    PubMed  CAS  Google Scholar 

  20. Campa D, Hung RJ, Mates D, et al. Lack of association between -251 T > A polymorphism of IL8 and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 2005, 14: 2457–2458.

    Article  PubMed  CAS  Google Scholar 

  21. Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev, 2006, 25: 417–434.

    Article  PubMed  CAS  Google Scholar 

  22. Kim J, Shao Y, Kim SY, et al. Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell, 2008, 19: 433–444.

    Article  PubMed  CAS  Google Scholar 

  23. Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 2006, 103: 159–166.

    Article  PubMed  CAS  Google Scholar 

  24. Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett, 2001, 79: 215–219.

    Article  PubMed  CAS  Google Scholar 

  25. Jiang DF, Liu WL, Lu YL, et al. Function of IL-18 in promoting metastasis of lung cancer. Chin J Cancer (Chinese), 2003, 25: 348–352.

    CAS  Google Scholar 

  26. Jung MK, Song HK, Kim KE, et al. IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol Lett, 2006, 107: 125–130.

    Article  PubMed  CAS  Google Scholar 

  27. Li H, Ge C, Yan M, et al. Hypoxia-Inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/Integrin beta 1 signaling in human hepatocellular carcinoma. Hepatology, 2011, 54: 910–919.

    Article  PubMed  CAS  Google Scholar 

  28. Cornish J, Gillespie MT, Callon KE, et al. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology, 2003, 144: 1194–1201.

    Article  PubMed  CAS  Google Scholar 

  29. Iwasaki T, Yamashita K, Tsujimura T, et al. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunotherapy, 2002, 25: 52–60.

    Article  Google Scholar 

  30. Gunel N, Cokun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer, 2002, 95: 663–667.

    Article  PubMed  CAS  Google Scholar 

  31. Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev, 2010, 21: 27–39.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urological Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, China

    Shaojun Nong, Yueping Zhang, Bin Cheng, Chongsheng He, Limin Ma, Shujun Zhou & Wenguang Li

Authors
  1. Shaojun Nong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yueping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chongsheng He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Limin Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shujun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenguang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaojun Nong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nong, S., Zhang, Y., Cheng, B. et al. Effect of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of prostate cancer patients. Chin. -Ger. J. Clin. Oncol. 12, 188–193 (2013). https://doi.org/10.1007/s10330-012-1071-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-012-1071-0

Key words

Search

Navigation